Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
UTHR Stock Chart & Stats
$418.58
$3.82(1.05%)
At close: 4:00 PM EST
$418.58
$3.82(1.05%)
Day’s Range― - ―
52-Week Range$266.98 - $459.48
Previous CloseN/A
Volume58.00K
Average Volume (3M)754.50K
Market Cap
$19.07B
Enterprise Value$10.83B
Total Cash (Recent Filing)$3.05B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)16.6
Beta0.49
Next Earnings
Oct 29, 2025EPS Estimate
7.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.41
Shares Outstanding45,226,260
10 Day Avg. Volume560,854
30 Day Avg. Volume754,500
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue3.52
Enterprise Value/Gross Profit3.95
Enterprise Value/Ebitda6.52
Forecast
1Y Price Target
$506.64Price Target Upside21.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Clinical DataUnited Therapeutics presented additional positive Phase 3 TETON-2 data at the European Respiratory Society Congress, providing further evidence that Tyvaso is well-positioned in IPF as an add-on or even backbone therapy.
Treatment EfficacyTyvaso showed a statistically significant improvement in the quality of life for patients with IPF, which could motivate patients to adhere to the medication regimen.
Bears Say
Adverse EventsDiscontinuations due to adverse events were higher for Tyvaso at 16.8% compared to 12.4% for placebo.
Study DiscontinuationThe discontinuation rate was higher in the Tyvaso arm, partly due to the need for nebulization four times daily, causing nebulizer fatigue.
United Therapeutics News
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $266.98 and its highest was $459.48 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $19.07B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 4 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Jul 30, 2025. The company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $7.295 by -$0.885.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 7.32.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 45,226,260 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $6.41 in its last earnings report, missing expectations of $7.295. Following the earnings report the stock price went down -5.246%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
United Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$506.64 (21.04% Upside)
$506.64 (21.04% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 306.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.88%
12-Months-Change
Fundamentals
Return on Equity
19.30%
Trailing 12-Months
Asset Growth
17.62%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet needs of patients with chronic and life-threatening conditions. The company operates primarily in the pulmonary and vascular disease sectors, offering therapies for conditions such as pulmonary arterial hypertension (PAH) and organ transplantation. Its core products include Remodulin, Tyvaso, and Orenitram, which are designed to improve the quality of life for patients suffering from these serious health issues.
UTHR Company Deck
UTHR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced perspective with strong financial results and strategic initiatives, including record revenue growth and pipeline advancements. However, competitive challenges and concerns regarding market perceptions and regulatory hurdles were also highlighted.View all UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$506.64
▲(21.04% Upside)
Technical Analysis
Ownership Overview
7.08% Insiders
22.55% Mutual Funds
0.30% Other Institutional Investors
43.07% Public Companies and
Individual Investors